Biogen’s SKYCLARYS becomes first approved treatment for Friedreich’s Ataxia in EU

In a landmark decision, the European Commission (EC) has authorized Biogen Inc.'s SKYCLARYS (omaveloxolone) for the treatment of Friedreich’s ataxia (FA) in adults and adolescents ... Read More